CD133 expression is not synonymous to immunoreactivity for AC133 and fluctuates throughout the cell cycle in glioma stem-like cells

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Barrantes Freer, Alonso ^a,b   Renovanz, Mirjam ^c   Eich, Marcus ^c   Braukmann, Alina ^c   Sprang, Bettina ^c   Spirin, Pavel ^d   Pardo, Luis A ^a   Giese, Alf ^c   Kim, Ella L ^b,c  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD133 ANTIGEN; EPITOPE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; PROM1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CANCER STEM CELL; CELL CYCLE; CELL SURFACE; CONTROLLED STUDY; FEMALE; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PREDICTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TREATMENT RESPONSE; CACO-2 CELL LINE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DIVISION; CHEMISTRY; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; GLIOMA; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; TUMOR CELL LINE;

AC133 ANTIGEN; ANTIGENS, CD; CACO-2 CELLS; CELL DIVISION; CELL LINE, TUMOR; EPITOPES; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; PEPTIDES; S PHASE;

EID: 84939186332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130519     Document Type: Article

References (58)

1. Corbeil D, Marzesco A, Wilsch-Braäuninger M, Huttner WB. The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Letters. 2010; 584: 1659-64. doi: 10.1016/j.febslet.2010.01.050 PMID: 20122930
2. Bauer N, Wilsch-Brauninger M, Karbanova J, Fonseca AV, Strauss D, Freund D, et al. Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-A role of the endocytic-exocytic pathway. EMBO Mol Med. 2011; 3(7): 398-409. doi: 10.1002/emmm. 201100147 PMID: 21591261
3. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18): 5821-8. PMID: 14522905
4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432(7015): 396-401. PMID: 15549107
5. Lathia JD, Hitomi M, Gallagher J, Gadani SP, Adkins J, Vasanji A, et al. Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death and Dis. 2011; 2: E200. doi: 10.1038/cddis.2011.80 PMID: 21881602
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120): 756-60. PMID: 17051156
7. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 Is Essential for Glioblastoma Stem Cell Maintenance. Stem Cells. 2013; 31: 857-69. doi: 10.1002/stem.1317 PMID: 23307586
8. Wei Y, Jiang Y, Zou F, Liu Y, Wang S, Xu N, et al. Activation of PI3K/Akt pathway by CD133-p85 interaction promotes tumorigenic capacity of glioma stem cells. Proc Natl Acad Sci U S A. 2013; 110(17): 6829-34. doi: 10.1073/pnas.1217002110 PMID: 23569237
9. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, et al. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 2008; 14(1): 123-9. doi: 10.1158/1078-0432.CCR-07-0932 PMID: 18172261
10. Yan X, Ma L, Yi D, Yoon JG, Diercks A, Foltz G, et al. A CD133-related gene expression signature identifies an aggressive glioblastoma subtype with excessive mutations. Proc Natl Acad Sci U S A. 2011; 108(4): 1591-6. doi: 10.1073/pnas.1018696108 PMID: 21220328
11. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, et al. Stem cell-related "selfrenewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008; 26(18): 3015-24. doi: 10.1200/JCO.2007.15.7164 PMID: 18565887
12. Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, et al. Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy. J Neurosurg. 2013; 119(5): 1145-55. doi: 10.3171/2013.7.JNS122417 PMID: 23991844
13. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuno MA, et al. Phase I trial of a multiepitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immonol Immunother. 2013; 62(1): 125-35. doi: 10.1007/s00262-012-1319-0 PMID: 22847020
14. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006; 5: 67. PMID: 17140455
15. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007; 67(9): 4010-5. PMID: 17483311
16. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 2008; 88(8): 808-15. doi: 10.1038/labinvest.2008.57 PMID: 18560366
17. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, et al. A hierarchy of selfrenewing tumor-initiating cell types in glioblastoma. Cancer cell. 2010; 17(4): 362-75. doi: 10.1016/j.ccr. 2009.12.049 PMID: 20385361
18. Clement V, Dutoit V, Marino D, Dietrich PY, Radovanovic I. Limits of CD133 as a marker of glioma selfrenewing cells. Int J Cancer. 2009; 125(1): 244-8. doi: 10.1002/ijc.24352 PMID: 19350631
19. Tchoghandjian A, Baeza N, Colin C, Cayre M, Metellus P, Beclin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol. 2010; 20(1): 211-21. doi: 10.1111/j.1750-3639.2009.00269.x PMID: 19243384
20. Kim KJ, Lee KH, Kim HS, Moon KS, Jung TY, Jung S, et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology. 2011; 31(5): 494-502. doi: 10.1111/j.1440-1789.2010.01194.x PMID: 21269333
21. Cheng JX, Liu BL, Zhang X. How powerful is CD133 as a cancer stem cell marker in brain tumors? Cancer Treat Rev. 2009; 35(5): 403-8. doi: 10.1016/j.ctrv.2009.03.002 PMID: 19369008
22. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 2008; 122(4): 761-8. PMID: 17955491
23. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, et al. Glioblastomaderived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 2008; 27(20): 2897-909. PMID: 18037961
24. Melguizo C, Prados J, González B, Ortiz R, Concha A, Alvarez P, et al. MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med. 2012; 10(250). doi: 10.1186/1479-5876-10-250 PMID: 23245659
25. Kase M, Minajeva A, Niinepuu K, Kase S, Vardja M, Asser T, et al. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme. Radiol Oncol. 2013; 47(4): 405-10. doi: 10.2478/raon-2013-0055 PMID: 24294187
26. Campos B, Herold-Mende CC. Insight into the complex regulation of CD133 in glioma. Int J Cancer. 2011; 128(3): 501-10. doi: 10.1002/ijc.25687 PMID: 20853315
27. Knights MJ, Kyle S, Ismail A. Characteristic features of stem cells in glioblastomas: From cellular biology to genetics. Brain Pathol. 2012; 22(5): 592-606. doi: 10.1111/j.1750-3639.2012.00573.x PMID: 22303870
28. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR, Corbeil D, et al. CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J Pathol. 2013; 229(3): 355-78. doi: 10.1002/path.4086 PMID: 22899341
29. Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J Oncol. 2012; 2012: 376894. doi: 10.1155/2012/376894 PMID: 22685459
30. Fargeas CA, Corbeil D, Huttner WB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: Prominin family gene products in need of a rational nomenclature. Stem Cells. 2003; 21(4): 506-8. PMID: 12832703
31. Fargeas CA, Karbanova J, Jászai J, Corbeil D. CD133 and membrane microdomains: Old facets for future hypotheses. World J Gastroenterol. 2011; 17(36): 4149-52. doi: 10.3748/wjg.v17.i36.4149 PMID: 22039332
32. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl) 2008; 86(9): 1025-32. doi: 10.1007/s00109-008-0357-8 PMID: 18535813
33. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 2010; 70(2): 719-29. doi: 10.1158/0008-5472.CAN-09-1820 PMID: 20068153
34. Mak AB, Blakely K, Williams RA, Penttilä PA, Shukalyuk AI, Osman KT, et al. CD133 protein Nglycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem. 2011; 286(47): 41046-56. doi: 10.1074/jbc.M111.261545 PMID: 21937449
35. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, Lancaster JR Jr, et al. CD133 Is a Marker of Bioenergetic Stress in Human Glioma. PLoS One. 2008; 3(11): E3655. doi: 10.1371/journal.pone. 0003655 PMID: 18985161
36. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res. 2008; 68(19): 8094-103. doi: 10.1158/0008-5472. CAN-07-6208 PMID: 18829568
37. Holmberg Olausson K, Maire C, Haidar S, Ling J, Learner E, Nister M, et al. Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. PLoS One. 2014; 9(9): E106694. doi: 10.1371/journal.pone.0106694 PMID: 25184684
38. Ding BS, James D, Iyer R, Falciatori I, Hambardzumyan D, Wang S, et al. Prominin 1/CD133 Endothelium Sustains Growth of Proneural Glioma. PLoS One. 2013; 8(4): E62150. doi: 10.1371/journal.pone. 0062150 PMID: 23637986
39. Barrantes-Freer A, Kim E, Bielanska J, Giese A, Mortensen L, Schulz-Schaeffer W, et al. Human glioma-initiating cells show a distinct immature phenotype resembling but not identical to NG2 glia. J Neuropathol Exp Neurol. 2013; 72(4): 307-24. doi: 10.1097/NEN.0b013e31828afdbd PMID: 23481707
40. Rousset M. The human colon carcinoma cell lines HT-29 and Caco-2: Two in vitro models for the study of intestinal differentiation. Biochimie. 1986; 68(9): 1035-40. PMID: 3096381
41. Jett M, Seed T, Jamieson G. Isolation and characterization of plasma membranes and intact nuclei from lymphoid cells. J Biol Chem. 1977; 252(6): 2134-42. PMID: 845166
42. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, et al. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer. 2010; 9: 39. doi: 10.1186/1476-4598-9-39 PMID: 20167130
43. Corbeil D, Röper K, Hellwig A, Tavian M, Miraglia S, Watt SM, et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 2000; 275(8): 5512-20. PMID: 10681530
44. Pelts M, Pandya SM, Oh CJ, Model MA. Thickness profiling of formaldehyde-fixed cells by transmission-through-dye microscopy. BioTechniques. 2011; 50(6): 389-96. doi: 10.2144/000113684 PMID: 21781039
45. Fox CH, Johnson FB, Whiting J, Roller PP. Formaldehyde fixation. Journal of Histochemistry & Cytochemistry. 1985; 33(8): 845-53.
46. Westphal M, Hänsel M, Hamel W, Kunzmann R, Hölzel F. Karyotype analyses of 20 human glioma cell lines. Acta Neurochir (Wien). 1994; 126(1): 17-26. PMID: 8154317
47. Son M, Woolard K, Nam D, Lee J, Fine H. SSEA-1 is an enrichement marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009; 4(5): 440-52. doi: 10.1016/j.stem.2009.03.003 PMID: 19427293
48. Lathia J, Gallagher J, Heddleston J, Wang J, Eyler C, Macswords J, et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell. 2010; 6(5): 421-32. doi: 10.1016/j.stem.2010.02.018 PMID: 20452317
49. Sun Y, Kong W, Falk A, Hu J, Zhou L, Pollard S, et al. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. PloS One. 2009; 4(5): E5498. doi: 10.1371/journal.pone.0005498 PMID: 19430532
50. Jaksch M, Munera J, Bajpai R, Terskikh A, Oshima RG. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res. 2008; 68(19): 7882-6. doi: 10.1158/0008-5472.CAN-08-0723 PMID: 18829544
51. Bonifacino J, Dasso M, Harford J, Lippincott-Schwartz J, Yamada K. Current Protocols in Cell Biology. John Wiley, New York, NY. 1998.
52. Bjursell G, Reichard P. Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese hamster ovary cells. J Biol Chem. 1973; 248(11): 3904-9. PMID: 4736079
53. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 2004; 319(1): 15-26. PMID: 15558321
54. Lehnus KS, Donovan LK, Huang X, Zhao N, Warr TJ, Pilkington GJ, et al. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells. Int J Oncol. 2013; 42(3): 1011-7. doi: 10.3892/ijo. 2013.1787 PMID: 23340741
55. Hakomori S. Tumor Malignancy Defined by Aberrant Glycosylation and Sphingo(glyco)lipid Metabolism. Cancer Res. 1996; 56: 5309-18. PMID: 8968075
56. Miraglia S, Godfrey W, Yin A, Atkins K, Warnke R, Holden J, et al. A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood. 1997; 90(12): 5013-21. PMID: 9389721
57. Mizrak D, Brittan M, Alison M. CD133: Molecule of the moment. J Pathol. 2008; 214(1): 3-9. PMID: 18067118
58. Hu Y, Smyth GK. ELDA: Extreme limiting diluation analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol. Methos. 2009; 347(1-2): 70-78.